The conference raised important points about unregulated growth opportunities and new pharmacy arena players.
The conference raised important points about value-based contracts and the specialty pharmacy space.
Is the drive to value-based care really accelerating? What can be done amidst all of the uncertainty? Expert shares insights from the J.P. Morgan 35th Annual Healthcare Conference.
This year’s J.P. Morgan Healthcare Conference will address some of the biggest managed care trends, including next-gen at-risk contracts and access to therapy as cancer trends towards a chronic condition.
Pharmaceutical manufacturer relationships and next-gen value based contracts are primed to accelerate value-derivation from your drug spend.
In an era when adherence to specialty pharmaceuticals is disturbingly low, value-based pricing needs real-world results, not single-arm accelerated trials.
Despite their proliferation, at-risk pharma contracts are still little more than value-based window dressing. Here are four critical components of contracts that can actually move the value meter in the right direction.
Insights from the 2016 edition of the largest gathering in specialty pharmacy.
Prior authorizations are here to stay. Are yours working against you? Find out.